ITeos Therapeutics Inc [NASDAQ: ITOS] slipped around -0.13 points on Monday, while shares priced at $10.13 at the close of the session, down -1.27%.
Compared to the average trading volume of 1.40M shares, ITOS reached a trading volume of 13069472 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about ITeos Therapeutics Inc [ITOS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ITOS shares is $13.11 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ITOS stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for ITeos Therapeutics Inc shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on May 28, 2025. The new note on the price target was released on May 28, 2025, representing the official price target for ITeos Therapeutics Inc stock. Previously, the target price had yet another raise to $9, while Leerink Partners analysts kept a Market Perform rating on ITOS stock.
The Price to Book ratio for the last quarter was 0.69, with the Price to Cash per share for the same quarter was set at 13.60.
How has ITOS stock performed recently?
ITeos Therapeutics Inc [ITOS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.13. With this latest performance, ITOS shares gained by 1.30% in over the last four-week period, additionally plugging by 30.88% over the last 6 months – not to mention a rise of 31.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ITOS stock in for the last two-week period is set at 56.61, with the RSI for the last a single of trading hit 0.17, and the three-weeks RSI is set at 0.23 for ITeos Therapeutics Inc [ITOS]. The present Moving Average for the last 50 days of trading for this stock 9.53, while it was recorded at 10.25 for the last single week of trading, and 8.16 for the last 200 days.
ITeos Therapeutics Inc [ITOS]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and ITeos Therapeutics Inc [ITOS] shares currently have an operating margin of -435.19% and a Gross Margin at 96.41%. ITeos Therapeutics Inc’s Net Margin is presently recorded at -373.75%.
ITeos Therapeutics Inc (ITOS) Capital Structure & Debt Analysis
According to recent financial data for ITeos Therapeutics Inc. ( ITOS), the Return on Equity (ROE) stands at -23.68%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -20.30%, reflecting the company’s efficiency in generating profits from its assets. Additionally, ITeos Therapeutics Inc’s Return on Invested Capital (ROIC) is -23.07%, showcasing its effectiveness in deploying capital for earnings.
ITeos Therapeutics Inc (ITOS) Efficiency & Liquidity Metrics
Based on ITeos Therapeutics Inc’s (ITOS) latest financial statements, the Debt-to-Equity Ratio is 0.01%, indicating its reliance on debt financing relative to shareholder equity.
ITeos Therapeutics Inc (ITOS) Efficiency & Liquidity Metrics
From an operational efficiency perspective, ITeos Therapeutics Inc. (ITOS) effectively leverages its workforce, generating an average of -$756127.17 per employee. The company’s liquidity position is robust, with a Current Ratio of 14.13% and a Quick Ratio of 14.13%, indicating strong ability to cover short-term liabilities.
Earnings analysis for ITeos Therapeutics Inc [ITOS]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ITOS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ITeos Therapeutics Inc go to 3.89%.
Insider trade positions for ITeos Therapeutics Inc [ITOS]
There are presently around $114.54%, or 115.85%% of ITOS stock, in the hands of institutional investors. The top three institutional holders of ITOS stocks are: BLACKROCK INC. with ownership of 3.73 million shares, which is approximately 9.3983%. RA CAPITAL MANAGEMENT, L.P., holding 3.52 million shares of the stock with an approximate value of $$52.2 million in ITOS stocks shares; and RA CAPITAL MANAGEMENT, L.P., currently with $$48.23 million in ITOS stock with ownership which is approximately 8.1862%.
